DK0658585T3 - Amidinophenylalaninderivater, fremgangsmåde til deres fremstilling, deres anvendelse og midler indeholdende disse som antik - Google Patents

Amidinophenylalaninderivater, fremgangsmåde til deres fremstilling, deres anvendelse og midler indeholdende disse som antik

Info

Publication number
DK0658585T3
DK0658585T3 DK94118551T DK94118551T DK0658585T3 DK 0658585 T3 DK0658585 T3 DK 0658585T3 DK 94118551 T DK94118551 T DK 94118551T DK 94118551 T DK94118551 T DK 94118551T DK 0658585 T3 DK0658585 T3 DK 0658585T3
Authority
DK
Denmark
Prior art keywords
antiques
processes
preparation
agents containing
amidinophenylalanine derivatives
Prior art date
Application number
DK94118551T
Other languages
English (en)
Inventor
Werner Dr Stueber
Rainer Di Koschinsky
Original Assignee
Stueber Werner
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stueber Werner filed Critical Stueber Werner
Application granted granted Critical
Publication of DK0658585T3 publication Critical patent/DK0658585T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
    • C07C317/48—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C07C317/50—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups at least one of the nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32—Polymers modified by chemical after-treatment
    • C08G65/329—Polymers modified by chemical after-treatment with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06104—Dipeptides with the first amino acid being acidic
    • C07K5/06113—Asp- or Asn-amino acid
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32—Polymers modified by chemical after-treatment
    • C08G65/329—Polymers modified by chemical after-treatment with organic compounds
    • C08G65/334—Polymers modified by chemical after-treatment with organic compounds containing sulfur
    • C08G65/3344—Polymers modified by chemical after-treatment with organic compounds containing sulfur containing oxygen in addition to sulfur
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Polymers & Plastics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Polyethers (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Separation Of Suspended Particles By Flocculating Agents (AREA)
  • Medicinal Preparation (AREA)
DK94118551T 1993-12-10 1994-11-25 Amidinophenylalaninderivater, fremgangsmåde til deres fremstilling, deres anvendelse og midler indeholdende disse som antik DK0658585T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4342154A DE4342154A1 (de) 1993-12-10 1993-12-10 Amidinophenylalaninderivate, Verfahren zu deren Herstellung, deren Verwendung und diese enthaltende Mittel als Antikoagulantien

Publications (1)

Publication Number Publication Date
DK0658585T3 true DK0658585T3 (da) 2000-11-27

Family

ID=6504667

Family Applications (1)

Application Number Title Priority Date Filing Date
DK94118551T DK0658585T3 (da) 1993-12-10 1994-11-25 Amidinophenylalaninderivater, fremgangsmåde til deres fremstilling, deres anvendelse og midler indeholdende disse som antik

Country Status (12)

Country Link
US (1) US5571844A (da)
EP (1) EP0658585B1 (da)
JP (1) JP3448119B2 (da)
KR (1) KR950017943A (da)
AT (1) ATE194851T1 (da)
AU (1) AU696532B2 (da)
CA (1) CA2137748C (da)
DE (2) DE4342154A1 (da)
DK (1) DK0658585T3 (da)
ES (1) ES2150461T3 (da)
GR (1) GR3034615T3 (da)
PT (1) PT658585E (da)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19512316A1 (de) * 1995-04-01 1996-10-02 Hoechst Ag Härtungsmittel für elastische Epoxidharz-Systeme
DE19533817C2 (de) * 1995-09-13 1999-12-09 Max Planck Gesellschaft Komplex-gebundene Hemmstoffe aktivierbarer Stoffwechselenzyme als molekulare Marker zur Diagnostik und Therapieüberwachung
US5840733A (en) * 1996-07-01 1998-11-24 Redcell, Canada, Inc. Methods and compositions for producing novel conjugates of thrombin inhibitors and endogenous carriers resulting in anti-thrombins with extended lifetimes
US20020064546A1 (en) * 1996-09-13 2002-05-30 J. Milton Harris Degradable poly(ethylene glycol) hydrogels with controlled half-life and precursors therefor
CA2316834C (en) * 1998-01-07 2006-01-03 Shearwater Polymers, Inc. Degradable heterobifunctional poly(ethylene glycol) acrylates and gels and conjugates derived therefrom
US6066673A (en) * 1998-03-12 2000-05-23 The Procter & Gamble Company Enzyme inhibitors
ATE307111T1 (de) * 1999-01-13 2005-11-15 Genentech Inc Serinprotease-inhibitoren
EP1212098A2 (en) * 1999-09-10 2002-06-12 The Procter & Gamble Company Enzyme inhibitors
US6723788B1 (en) 1999-09-10 2004-04-20 The Procter & Gamble Company Enzyme inhibitors
AU7125700A (en) 1999-09-10 2001-04-10 Procter & Gamble Company, The Enzyme inhibitors
FR2816621A1 (fr) * 2000-11-13 2002-05-17 Bioracs Resines de polystyrene fonctionnalise par des groupements methyl ester de la l-tyrosine et leurs applications
DE10102878A1 (de) * 2001-01-23 2002-08-01 Haemosys Gmbh Oligo- oder Polyalkylengekoppelte Thrombininhibitoren
DE10330900B4 (de) * 2003-07-01 2006-09-14 Leibniz-Institut Für Polymerforschung Dresden E.V. Biomaterial mit einem modularen Beschichtungssystem zur Anwendung in Medizinprodukten mit direktem Blutkontakt

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4093712A (en) * 1974-11-08 1978-06-06 Mitsubishi Chemical Industries Limited N2 -arylsulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof
JPS60176586A (ja) * 1984-02-21 1985-09-10 Sanwa Kagaku Kenkyusho:Kk 新規な修飾ウロキナ−ゼ、その製法並びにこれを含有する血栓溶解剤
PT84171B (pt) * 1986-01-24 1989-03-30 Sanofi Sa Processo para a preparacao de derivados das n alfa-aril-sulfonilamiminoacil-p- -amidinofenil-alaninamidas, bem como dos seus derivados de sintese e das composicoes farmaceuticas que os contem
FR2593813A1 (fr) * 1986-01-24 1987-08-07 Sanofi Sa Derives des na-arylsulfonylaminoacyl p-amidinophenylalaninamides, leur procede de preparation, leur application comme medicaments et les compositions les renfermant
DE3819079A1 (de) * 1988-06-04 1989-12-07 Hoechst Ag Hirudin-derivate mit verzoegerter wirkung
GB2247239A (en) * 1990-08-22 1992-02-26 Ciba Geigy Ag Hirudin conjugates with polyoxyethylene
DE4111394A1 (de) * 1991-04-09 1992-10-15 Behringwerke Ag Amidinophenylalaninderivate, verfahren zu deren herstellung, deren verwendung und diese enthaltende mittel
DE4115468A1 (de) * 1991-05-11 1992-11-12 Behringwerke Ag Amidinophenylalaninderivate, verfahren zu deren herstellung, deren verwendung und diese enthaltende mittel als antikoagulantien
DE4206858A1 (de) * 1992-03-05 1993-09-09 Behringwerke Ag Glycopeptid-derivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende pharmazeutische mittel

Also Published As

Publication number Publication date
PT658585E (pt) 2001-01-31
KR950017943A (ko) 1995-07-22
DE4342154A1 (de) 1995-06-14
GR3034615T3 (en) 2001-01-31
JPH07206927A (ja) 1995-08-08
JP3448119B2 (ja) 2003-09-16
EP0658585A2 (de) 1995-06-21
US5571844A (en) 1996-11-05
CA2137748C (en) 2004-07-13
ATE194851T1 (de) 2000-08-15
EP0658585B1 (de) 2000-07-19
AU8032794A (en) 1995-06-15
ES2150461T3 (es) 2000-12-01
EP0658585A3 (de) 1995-10-18
DE59409456D1 (de) 2000-08-24
CA2137748A1 (en) 1995-06-11
AU696532B2 (en) 1998-09-10

Similar Documents

Publication Publication Date Title
NO302570B1 (no) Substituerte pipekolinsyrederivater som HIV-protease-inhibitorer, farmasöytiske blandinger inneholdende dem og anvendelser av derivatene
DK0693073T3 (da) Bicykliske ansamyciner og deres anvendelse som antitumormidler
DK1246809T3 (da) 5-aryl-1H-1,2,4-triazolforbindelser som inhibitor for cyclooxygenase-2 og farmaceutiske sammensætninger som indeholder dem
DK0813525T3 (da) Benzamidinderivater, deres fremstilling og anvendelse som antikoagulanter
DK0705254T3 (da) Phenylheterocykliske forbindelser som cyclooxygenase-2-inhibitorer
NO932620L (no) Amindiol-proteaseinhibitorer
ES2175624T3 (es) Derivados de pirazolo(4,3-d)pirimidina y composiciones farmaceuticas que los contienen.
DK1254899T3 (da) Piperazinderivater og deres anvendelse som anti-inflammatoriske midler
NO20006323D0 (no) Glykopeptidderivater og farmasöytiske sammensetninger som inneholder disse
CL2004000849A1 (es) Compuestos derivados de benzamidas-2-hidroxi-3-diaminoalcanos, utiles para el tratamiento o la prevencion de alzheimer, sindrome de down, hemorragia cerebral hereditaria, demencias degenerativas y otras.
NO923744D0 (no) Nye 2-substituerte indan-2-mercaptoacetylamidderivater anvendbare som inhibitorer av enkefalinase og ace
FI942423A0 (fi) Sakkariinijohdannisia proteolyyttisen entsyymin inhibiittoreina
DK0548114T5 (da) Mometason-furoat-monohydrat, fremgangsmåde til fremtilling deraf og farmaceutiske præparater indeholdende dette
BR9807508A (pt) Inibidores de sulfamida da metaloprotease
DK0513543T3 (da) Amidinophenylalaninderivater, fremgangsmåde til deres fremstilling, deres anvendelse og antikoagulationsmidler med indehold deraf
DK0658585T3 (da) Amidinophenylalaninderivater, fremgangsmåde til deres fremstilling, deres anvendelse og midler indeholdende disse som antik
NO954768D0 (no) N-alkyltiopolyaminderivater som radiobeskyttende midler
BR9916004A (pt) Inibidores de proteinase c de pró-colágeno
NO975681L (no) Benzisoxazol- og indazol-derivater som antipsykotiske midler
DK0632026T3 (da) Alfa-aminosyrederivater, en fremgangsmåde til deres fremstilling og farmaceutiske sammensætninger, der indeholder dem
NO963331L (no) 5-Heteroarylindol-derivater som benzodiazepin-reseptorsete-agonister og antagonister
NO983511D0 (no) Difenylstilbener som pro-legemidler for COX-2-inhibitorer
DK0758312T3 (da) Substituerede fusionerede og broforbundne bicykliske forbindelser som terapeutiske midler
NO20002408L (no) 5-HT1F antagonister
DK0998471T3 (da) Heterocykliske forbindelser, fremgangsmåde til fremstilling heraf og farmaceutiske sammensætninger, som indeholder disse